AstraZeneca plans to conduct further development of AZD3480 by initiating phase-IIb studies in attention deficit/hyperactivity disorder (ADHD) and has agreed to make a $10 million milestone payment to Targacept.

AstraZeneca also plans to continue development of AZD1446 (TC-6683) for Alzheimer's disease. AZD1446 is currently in phase-1 and was discovered in the ongoing AstraZeneca-Targacept research collaboration.

For Alzheimer's disease, development of AZD1446 has been prioritized by AstraZeneca over further development of AZD3480. AZD3480 and AZD1446 are selective alpha4beta2 NNR agonists.